13F Holdings
中文EN

INVA Innoviva, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1080014 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.8%
TTM net income YoY51.9%
TTM EPS YoY41.6%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR57.1%

Margins

Gross margin74.5%
Operating margin38.8%
Net margin44.1%
FCF margin41.6%
EBITDA margin—

Returns

ROE18.0%
ROA13.0%
ROIC (approx.)18.3%
Asset turnover0.30x

Leverage & solvency

Liabilities / assets26.0%
Debt / equity0.23x
Current ratio15.44x
Interest coverage8.64x

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio0.7%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$411.33M$358.71M$310.46M$331.34M$391.87M
Gross profit$307.67M$296.21M$246.04M——
R&D expense$30.60M$13.65M$33.92M$41.43M$576,000
SG&A expense$113.32M$115.69M$98.23M$63.54M$16.19M
Operating income$163.75M$166.87M$113.89M—$375.10M
Interest expense$16.70M$22.21M$19.16M$15.79M$19.07M
Pretax income$326.86M$37.39M$194.10M$286.95M$445.28M
Income tax$55.70M$14.00M$14.38M$66.69M$76.44M
Net income$271.17M$23.39M$179.72M$213.92M$265.85M
EBITDA————$388.94M
EPS (basic)4.020.372.753.073.24
EPS (diluted)3.300.362.202.372.87
Weighted avg. shares (diluted)84.76M74.19M86.88M95.25M94.31M
Balance sheet
Cash & equivalents$550.94M$304.96M$193.51M$291.05M$201.53M
Short-term investments————$0
Inventory$39.17M$33.73M$40.74M$55.90M$0
Current assets$727.51M$554.31M$344.22M$443.51M$313.67M
PP&E, net$1.55M$514,000$483,000$170,000$12,000
Goodwill$17.91M$17.91M$17.91M$26.71M$0
Intangibles$182.16M$208.43M$230.34M$252.92M$0
Total assets$1.64B$1.30B$1.24B$1.23B$926.39M
Current liabilities$49.70M$236.08M$38.13M$134.97M$5.81M
Short-term debt$0$192.03M$0$96.19M$0
Long-term debt$257.73M$256.32M$446.23M$444.18M$394.65M
Total debt$257.73M$448.34M$446.23M$540.37M$394.65M
Total liabilities$462.32M$609.90M$568.55M$665.71M$400.46M
Shareholders' equity$1.17B$691.16M$674.96M$565.79M$414.74M
Net debt-$293.21M$143.38M$252.72M$249.32M$193.13M
Shares outstanding74.64M62.66M63.31M69.19M69.57M
Cash flow statement
Operating cash flow$196.93M$188.69M$141.06M$201.73M$363.81M
Capital expenditure$1.13M$270,000$411,000$67,000$0
Free cash flow$195.80M$188.42M$140.65M$201.66M$363.81M
Investing cash flow$40.50M-$63.79M-$66.76M-$56.63M$43.72M
Financing cash flow$8.55M-$13.45M-$171.84M-$55.57M-$452.50M
Depreciation & amortization————$13.83M
Stock-based compensation$9.45M$6.37M$5.84M$7.35M$2.02M
Dividends paid————$0
Share buybacks$4.53M$14.78M$75.73M$8.50M$394.15M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.